Stellar Biotechnology: Corporate Presentation (Stellar Biotechnologies) - Dec 18, 2016 - Anticipated preliminary data from P2 trial (NCT02665364) for lupus in 2017; Anticipated conditional approval in Korea for lupus in 2018
Anticipated non-US regulatory • Anticipated P2 data • Lupus
|